Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Accounts Payables (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Accounts Payables for 15 consecutive years, with $16.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 130.35% to $16.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.2 million, a 130.35% increase, with the full-year FY2024 number at $12.0 million, up 19.01% from a year prior.
  • Accounts Payables was $16.2 million for Q3 2025 at Usana Health Sciences, down from $17.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $18.2 million in Q1 2021 to a low of $6.6 million in Q2 2024.
  • A 5-year average of $11.7 million and a median of $11.1 million in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: decreased 28.31% in 2024, then soared 169.24% in 2025.
  • Usana Health Sciences' Accounts Payables stood at $13.7 million in 2021, then decreased by 19.39% to $11.0 million in 2022, then dropped by 8.86% to $10.1 million in 2023, then increased by 19.01% to $12.0 million in 2024, then skyrocketed by 35.34% to $16.2 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Accounts Payables are $16.2 million (Q3 2025), $17.9 million (Q2 2025), and $14.0 million (Q1 2025).